08:41 AM EDT, 03/12/2026 (MT Newswires) -- MBX Biosciences ( MBX ) reported Q4 net loss Thursday of $0.49 per diluted share, widening from a loss of $0.47 a year earlier.

Analysts polled by FactSet expected a loss of $0.63.

As expected, no revenue for the quarter ended Dec. 31 was reported.

The company held pro forma cash and investments of $459.1 million as of Dec. 31, and expected its combined cash, cash equivalents, and marketable securities balance to fund operations into 2029.

Shares of the company were down 1.2% in premarket activity.